A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
IsraelRecruitingPHASE2
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Conditions
Gynecologic Cancers · Platinum-Sensitive Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer (PSOC)
Locations
- Holy Name Medical Center /ID# 279017, Teaneck, New Jersey, United States
- Providence Portland Medical Center /ID# 277727, Portland, Oregon, United States
- Women & Infants Hospital /ID# 277930, Providence, Rhode Island, United States
- SCRI Oncology Partners /ID# 279733, Nashville, Tennessee, United States
- Texas Oncology-Austin North /ID# 279958, Austin, Texas, United States
- Next Virginia /ID# 279684, Fairfax, Virginia, United States
- Rabin Medical Center /ID# 279142, Petah Tikva, Central District, Israel
- The Chaim Sheba Medical Center /ID# 275997, Ramat Gan, Tel Aviv, Israel
- Tel Aviv Sourasky Medical Center /ID# 275852, Tel Aviv, Tel Aviv, Israel
- Rambam Health Care Campus- Haifa /ID# 276004, Haifa, Israel
- Shaare Zedek Medical Center /ID# 275854, Jerusalem, Israel
- Hyogo Cancer Center /ID# 276940, Akashi-shi, Hyōgo, Japan
- National Cancer Center Hospital /ID# 276715, Chuo-Ku, Tokyo, Japan
- The Cancer Institute Hospital Of JFCR /ID# 276711, Koto-ku, Tokyo, Japan